User:Mr. Ibrahem/Lecanemab

Lecanemab, sold under the brand name Leqembi, is a medication used to treat Alzheimer disease. It is used in those with mild disease, were it has been shown to reduce amyloid plaque. The benefits do not appear meaningful. It is given by gradual injection into a vein.

Common side effects include headache, infusion reactions, and brain swelling. Other side effects may include amyloid related imaging abnormalities (ARIA). It is a monoclonal antibody that attaches to amyloid beta.

Lecanemab was approved for medical use in the United States in 2023. In 2023 the manufacturer submitted a request for approval in Europe. It is not approved in Canada. It is to cost about US$26,500 per year for a 75 kg person.